Tags

Type your tag names separated by a space and hit enter

Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CLpro Reporter Assay.
J Virol. 2020 10 27; 94(22)JV

Abstract

In late 2019, a human coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged, likely from a zoonotic reservoir. This virus causes COVID-19, has infected millions of people, and has led to hundreds of thousands of deaths across the globe. While the best interventions to control and ultimately stop the pandemic are prophylactic vaccines, antiviral therapeutics are important to limit morbidity and mortality in those already infected. At this time, only one FDA-approved anti-SARS-CoV-2 antiviral drug, remdesivir, is available, and unfortunately, its efficacy appears to be limited. Thus, the identification of new and efficacious antivirals is of the highest importance. In order to facilitate rapid drug discovery, flexible, sensitive, and high-throughput screening methods are required. With respect to drug targets, most attention is focused on either the viral RNA-dependent RNA polymerase or the main viral protease, 3CLpro 3CLpro is an attractive target for antiviral therapeutics, as it is essential for processing newly translated viral proteins and the viral life cycle cannot be completed without protease activity. In this work, we report a new assay to identify inhibitors of 3CLpro Our reporter is based on a green fluorescent protein (GFP)-derived protein that fluoresces only after cleavage by 3CLpro This experimentally optimized reporter assay allows for antiviral drug screening in human cell culture at biosafety level 2 (BSL2) with high-throughput compatible protocols. Using this screening approach in combination with existing drug libraries may lead to the rapid identification of novel antivirals to suppress SARS-CoV-2 replication and spread.IMPORTANCE The COVID-19 pandemic has already led to more than 700,000 deaths and innumerable changes to daily life worldwide. Along with development of a vaccine, identification of effective antivirals to treat infected patients is of the highest importance. However, rapid drug discovery requires efficient methods to identify novel compounds that can inhibit the virus. In this work, we present a method for identifying inhibitors of the SARS-CoV-2 main protease, 3CLpro This reporter-based assay allows for antiviral drug screening in human cell culture at biosafety level 2 (BSL2) with high-throughput compatible sample processing and analysis. This assay may help identify novel antivirals to control the COVID-19 pandemic.

Authors+Show Affiliations

Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA.Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA.Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA nicholas.heaton@duke.edu.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32843534

Citation

Froggatt, Heather M., et al. "Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CLpro Reporter Assay." Journal of Virology, vol. 94, no. 22, 2020.
Froggatt HM, Heaton BE, Heaton NS. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CLpro Reporter Assay. J Virol. 2020;94(22).
Froggatt, H. M., Heaton, B. E., & Heaton, N. S. (2020). Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CLpro Reporter Assay. Journal of Virology, 94(22). https://doi.org/10.1128/JVI.01265-20
Froggatt HM, Heaton BE, Heaton NS. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CLpro Reporter Assay. J Virol. 2020 10 27;94(22) PubMed PMID: 32843534.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CLpro Reporter Assay. AU - Froggatt,Heather M, AU - Heaton,Brook E, AU - Heaton,Nicholas S, Y1 - 2020/10/27/ PY - 2020/06/22/received PY - 2020/08/20/accepted PY - 2020/8/28/pubmed PY - 2020/11/3/medline PY - 2020/8/27/entrez KW - FlipGFP KW - antivirals KW - coronavirus KW - protease KW - screening JF - Journal of virology JO - J Virol VL - 94 IS - 22 N2 - In late 2019, a human coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged, likely from a zoonotic reservoir. This virus causes COVID-19, has infected millions of people, and has led to hundreds of thousands of deaths across the globe. While the best interventions to control and ultimately stop the pandemic are prophylactic vaccines, antiviral therapeutics are important to limit morbidity and mortality in those already infected. At this time, only one FDA-approved anti-SARS-CoV-2 antiviral drug, remdesivir, is available, and unfortunately, its efficacy appears to be limited. Thus, the identification of new and efficacious antivirals is of the highest importance. In order to facilitate rapid drug discovery, flexible, sensitive, and high-throughput screening methods are required. With respect to drug targets, most attention is focused on either the viral RNA-dependent RNA polymerase or the main viral protease, 3CLpro 3CLpro is an attractive target for antiviral therapeutics, as it is essential for processing newly translated viral proteins and the viral life cycle cannot be completed without protease activity. In this work, we report a new assay to identify inhibitors of 3CLpro Our reporter is based on a green fluorescent protein (GFP)-derived protein that fluoresces only after cleavage by 3CLpro This experimentally optimized reporter assay allows for antiviral drug screening in human cell culture at biosafety level 2 (BSL2) with high-throughput compatible protocols. Using this screening approach in combination with existing drug libraries may lead to the rapid identification of novel antivirals to suppress SARS-CoV-2 replication and spread.IMPORTANCE The COVID-19 pandemic has already led to more than 700,000 deaths and innumerable changes to daily life worldwide. Along with development of a vaccine, identification of effective antivirals to treat infected patients is of the highest importance. However, rapid drug discovery requires efficient methods to identify novel compounds that can inhibit the virus. In this work, we present a method for identifying inhibitors of the SARS-CoV-2 main protease, 3CLpro This reporter-based assay allows for antiviral drug screening in human cell culture at biosafety level 2 (BSL2) with high-throughput compatible sample processing and analysis. This assay may help identify novel antivirals to control the COVID-19 pandemic. SN - 1098-5514 UR - https://www.unboundmedicine.com/medline/citation/32843534/Development_of_a_Fluorescence_Based_High_Throughput_SARS_CoV_2_3CLpro_Reporter_Assay_ L2 - http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=32843534 DB - PRIME DP - Unbound Medicine ER -